2019
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko Y, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal Of Hematology 2019, 95: 151-155. PMID: 31709579, PMCID: PMC8025136, DOI: 10.1002/ajh.25674.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overDisease-Free SurvivalEnteropathy-Associated T-Cell LymphomaFemaleHematopoietic Stem Cell TransplantationHumansIncidenceLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm ProteinsReceptors, Antigen, T-Cell, gamma-deltaSurvival RateTransplantation, AutologousConceptsHepatosplenic T-cell lymphomaT-cell lymphomaEnteropathy-Associated T-Cell LymphomaGamma-delta T-cell lymphomaT-cell ProjectStem cell transplantationCell lymphomaRare subtypeFirst remissionTreatment patternsCell transplantationAutologous stem cell transplantationAllogeneic stem cell transplantationFirst-line therapyLarge prospective trialsProgression-free survivalCells projectRare T cellsNovel treatment approachesFree survivalLine therapyOverall survivalProspective trialAnthracycline regimensClinical trials
2015
A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial
Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma (PTCL): final results from the T‐ cell consortium trial. British Journal Of Haematology 2015, 172: 535-544. PMID: 26627450, PMCID: PMC5642048, DOI: 10.1111/bjh.13855.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaStem cell transplantationT-cell lymphomaFront-line therapyLine therapyCell lymphomaRefractory peripheral T-cell lymphomaConsolidative stem cell transplantationAngioimmunoblastic T-cell lymphomaAnaplastic large cell lymphomaConventional CHOP chemotherapyPhase II studyStage IV diseaseFront-line settingPhase 2 studyProgression-free survivalInternational Prognostic IndexLarge cell lymphomaFebrile neutropeniaPTCL patientsCHOP chemotherapyLiver transaminasesPartial remissionConsortium TrialII study
2013
Treatment strategies for peripheral T-cell lymphomas
Foss FM. Treatment strategies for peripheral T-cell lymphomas. Best Practice & Research Clinical Haematology 2013, 26: 43-56. PMID: 23768640, DOI: 10.1016/j.beha.2013.04.005.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAggressive first-line therapyAutologous stem cell transplantationConventional lymphoma therapyFirst-line therapyMajority of patientsStem cell transplantationSignal transduction inhibitorsHistone deacetylase inhibitorsFuture novel approachesLine therapyTransplant candidatesImproved survivalRelevant pathwaysAggressive diseaseCell transplantationInferior outcomesLymphoma therapyTransduction inhibitorsTreatment strategiesDeacetylase inhibitorsMonoclonal antibodiesMolecular profilingHeterogeneous group
2003
Peripheral T- cell lymphomas: diagnosis and management
Dearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management. Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.Peer-Reviewed Original ResearchConceptsFirst-line therapyT-cell lymphomaCampath-1HResponse rateLine therapyPurine analoguesT-PLLAllogeneic bone marrow transplantationPeripheral T-cell lymphomaThird of patientsFavorable prognostic factorBone marrow transplantationMonoclonal antibody therapyStem cell transplantationNon-randomized studiesMature T-cell neoplasmsMinimal residual diseaseT-cell neoplasmsHigh response rateT-cell malignanciesLargest disease groupRisk of toxicityDurable remissionsRefractory patientsPreparative regimens